In patients with EGFR-mutated lung cancer, T790M mutations, MET amplifications, and other AGAs are among the acquired mechanisms of resistance to prior EGFR therapies, allowing for therapeutic options beyond chemotherapy. Here, EGFR is linked to lung carcinoma.